acquir array kol call array initi attach qt
creat bluematrix
today array ow cover kumar announc
enter definit merger agreement acquir
arri commerci stage compani focus discoveri develop
commerci target small molecul medicin treat cancer
diseas high unmet need total enterpris valu think
good news underscor belief pipelin first class and/
best class compound remain underappreci
interestingli announc jeff settleman ph join
compani senior vice presid group head oncolog research
develop lead earli oncolog research discoveri proof
concept clinic studi dr settleman leader molecularli target cancer
therapeut epigenet cancer drug resist person cancer
pleas see link kol call array product array initi
 kumar dial call
passcod host compani call today et
approv combin use braftovi
encorafenib mektovi binimetinib treatment
mutant unresect metastat melanoma expect financ
major transact debt balanc exist cash
transact expect dilut ep
neutral accret begin addit accret
growth anticip thereaft provid appropri updat
current guidanc conjunct earn releas
reiter ow rate think respect earn growth driven
innov medicin pipelin advanc return capit
sharehold industri averag underappreci therefor
believ multipl expans upward earn revis drive share
use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk invest thesi price target
product repres signific portion sale could face gener
competit current portfolio product may face competit cannib
pipelin introduct new competit could diminish price
power exist drug record direct product and/or allianc revenu
billion nine biopharmaceut product prevnar lyrica
ibranc eliqui enbrel lipitor xeljanz viagra sutent account total
revenu product pfizer major product subject
problem loss patent protect applic chang prescript growth rate
affect doctor patient confid pressur exist competit product chang
label access pressur new more-effect treatment introduc
advers impact revenu could signific
pipelin delay failur and/or higher-than-forecast competit gener
may continu face access challeng biosimilar product market
biosimilar product may receiv access pariti innov product remain
disadvantag posit exampl inflectra/remsima experienc access challeng
risk relat strateg acquisit success acquisit hospira
anacor mediv astrazeneca small molecul anti-infect busi depend
larg part compani abil realiz anticip benefit combin
busi exist segment exampl may fail achiev anticip
cost save acquisit hospira cost save within expect time
frame accret impact anticip acquisit hospira anacor
mediv may realiz may delay also may fail gener revenu
growth acquir busi expect time enter transact
pfizer inc engag discoveri develop manufactur healthcar product
price close jun
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
lead co-manag cantor fitzgerald and/or affili act lead co-manag public offer equiti and/or debt secur array
biopharma inc within last month
invest bank last month cantor fitzgerald and/or affili receiv compens invest bank servic last month
array biopharma inc
cantor fitzgerald and/or affili market maker array biopharma inc
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
materi approv distribut unit kingdom cantor fitzgerald europ cfe cfe authoris regul
conduct author fca believ inform materi upon inform base accur except
oblig rule fca guarante accuraci materi intend use elig counterparti profession
client fall within articl servic market act promot order gener invest
public none invest invest servic mention describ herein avail person particular
avail retail client defin rule fca
disclosur canadian institut investor
research report prepar analyst cantor fitzgerald co cantor fitzgerald canada corpor result report
prepar subject canadian disclosur requir cantor fitzgerald canada may distribut research report prepar affili
financi instrument discuss report may suitabl investor investor must make invest decis base
specif invest object past perform taken indic guarante futur perform price valu
incom financi instrument featur report rise well fall affect chang econom financi polit
factor financi instrument denomin currenc investor currenc chang exchang rate may advers affect price
valu incom deriv financi instrument investor effect assum currenc risk addit investor secur
adr whose valu affect currenc home market underli secur effect assum currenc risk
rate price target histori pfizer inc
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
rate price target histori array biopharma inc arri
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
distribut ratings/invest bank servic ib
addit inform avail request copyright cantor fitzgerald
head healthcar research
